3 US Generics Formulations Maker, Respiratory and Anti-Infective Leader and Contract Formulations Producer Stocks With a Strong Future Roadmap: Strides Pharma Science, Cipla and Innova Captab

US generics, respiratory and contract stocks bring together companies with a visible plan for the years ahead. Strides Pharma Science, Cipla and Innova Captab cover a US generics formulations maker, a respiratory and anti-infective leader and a contract formulations producer.

This list covers three US generics, respiratory and contract stocks with complete current figures: Strides Pharma Science, Cipla and Innova Captab. Every figure comes from the latest reported financials and the 26 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are US Generics, Respiratory and Contract Stocks?

US generics, respiratory and contract stocks are listed drug makers that sell generics in regulated markets, respiratory and chronic brands in India and formulations made for other companies. Their earnings depend on launches, approvals, plant quality and prescriptions.

US Generics, Respiratory and Contract Stocks at a Glance

On valuation, Strides Pharma Science and Cipla trade at a P/E below the industry P/E, while Innova Captab trades above it, which reflects the growth the market already expects. Readers comparing US generics, respiratory and contract stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do US Generics, Respiratory and Contract Stocks Have a Strong Roadmap in India?

US generics, respiratory and contract stocks have a strong roadmap in India because a wide product pipeline, trusted brands and outsourced manufacturing keep widening the revenue base.

• Product pipeline. New launches in regulated markets add revenue.
• Brand trust. Respiratory and chronic brands retain prescribers.
• Contract work. Other drug companies outsource formulations.

Why Strides Pharma Science Features Among These US Generics, Respiratory and Contract Stocks

Among the US generics, respiratory and contract stocks on this list, Strides Pharma Science, based in Bengaluru, makes finished dosage generics for the United States and other regulated markets, with oral solids and soft gel capsules as important product groups.

The company has a return on equity of 17.9%, a debt to equity ratio of 0.57 and a market capitalisation of Rs 9,491 crore. The stock trades at a P/E of 15.0, below the industry P/E of 36.0.

Revenue rose from Rs 3,202 crore in FY22 to Rs 5,009 crore in FY26, a compound annual growth rate of 11.8%. Net profit grew from Rs 409 crore in FY25 to Rs 575 crore in FY26, a rise of 40.3%. In the June 2026 quarter, revenue grew 12.6% year on year to Rs 1,270 crore, while net profit rose 56.7% to Rs 165 crore.

Roadmap: The company is leaning on new product launches in its regulated-market pipeline and improving utilisation of its plants. Profit can rise faster than revenue as volumes build on an existing cost base.

What to watch: Track new US launches and the pace of price erosion in generic categories.

Why Cipla Features Among These US Generics, Respiratory and Contract Stocks

Among the finished dose generics company shares on this list, Cipla is a Mumbai-based pharmaceutical company with strengths in respiratory medicines, anti-infectives and chronic therapies. It sells branded and generic products in India, South Africa, the United States and other markets.

Revenue rose from Rs 22,044 crore in FY22 to Rs 29,045 crore in FY26, a compound annual growth rate of 7.1%. Net profit grew from Rs 2,559 crore in FY22 to Rs 3,870 crore in FY26, which works out to a compound annual growth rate of 10.9%.

In the June 2026 quarter, revenue grew 1.6% year on year to Rs 7,330 crore. The company has a return on equity of 11.3%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 107,528 crore. The stock trades at a P/E of 32.0, below the industry P/E of 36.0.

Roadmap: The company is deepening its position in respiratory and complex generic products while expanding its consumer health and domestic prescription brands. A wide global footprint spreads its earnings across several markets.

What to watch: Follow new product launches in the United States and the growth of key domestic brands.

Why Innova Captab Features Among These US Generics, Respiratory and Contract Stocks

Among the three companies on this list, Innova Captab is a Himachal Pradesh-based pharmaceutical company that makes formulations for other pharma companies, manufactures its own branded generics and supplies active ingredients.

In the June 2026 quarter, revenue grew 32.8% year on year to Rs 473 crore, while net profit rose 42.3% to Rs 44.1 crore. Revenue rose from Rs 803 crore in FY22 to Rs 1,637 crore in FY26, a compound annual growth rate of 19.5%.

Net profit grew from Rs 64.0 crore in FY22 to Rs 141 crore in FY26, which works out to a compound annual growth rate of 21.8%. The company has a return on equity of 12.9%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 5,736 crore. The stock trades at a P/E of 37.2, above the industry P/E of 36.0.

Roadmap: The company combines contract manufacturing with its own branded generics business, which lets it capture more of the value chain. It has also been expanding capacity and widening its customer base.

What to watch: Watch the growth in the branded business and the utilisation of expanded capacity.

Strides Pharma Science vs Cipla vs Innova Captab on Key Financials

The table below sets the three US generics, respiratory and contract stocks side by side on revenue, profit and margin, using reported figures.

Strides Pharma Science posts the highest return on equity in this group at 17.9%. Cipla has the largest FY26 revenue at Rs 29,045 crore, and Innova Captab shows the fastest revenue growth with a 19.5% compound annual rate. A useful habit with US generics, respiratory and contract stocks is to check each new quarterly result against the capacity plans the company described earlier.

The June 2026 quarter, the latest reported, gives a fresh read on momentum:

Key Risks to Check Before Investing in US Generics, Respiratory and Contract Stocks

Every theme carries risks that deserve a check before any decision. For these US generics, respiratory and contract stocks, the main points are: Long-term finished dose generics company shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Regulatory checks. Plant inspections can affect approvals.
• Price pressure. Generic prices abroad can fall.
• Currency moves. Export earnings move with the rupee.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter US generics, respiratory and contract stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on US Generics, Respiratory and Contract Stocks

US generics, respiratory and contract stocks suit investors who prefer to study business strength before price moves. Strides Pharma Science, Cipla and Innova Captab each have a clear plan to grow. Based on the 26 October 2026 close, Strides Pharma Science trades at Rs 1,033.1, Cipla at Rs 1,355 and Innova Captab at Rs 998.2. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these US generics, respiratory and contract stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track US generics, respiratory and contract stocks, set price alerts and get research-backed stock ideas.

What are US generics, respiratory and contract stocks?

Ans. US generics, respiratory and contract stocks are listed drug makers that sell generics in regulated markets, respiratory and chronic brands in India and formulations made for other companies. Their earnings depend on launches, approvals, plant quality and prescriptions. This list looks at three of them, Strides Pharma Science, Cipla and Innova Captab, using reported FY22 to FY26 financials and the 26 October 2026 closing prices.

Which US generics, respiratory and contract stocks are covered in this list?

Ans. This list covers Strides Pharma Science, Cipla and Innova Captab. Based on the 26 October 2026 close, Strides Pharma Science traded at Rs 1,033.1, Cipla at Rs 1,355 and Innova Captab at Rs 998.2. Their return on equity ranges from 11.3% to 17.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.1% to 19.5%.

Why do US generics, respiratory and contract stocks have a strong future roadmap in India?

Ans. US generics, respiratory and contract stocks have a strong roadmap in India because a wide product pipeline, trusted brands and outsourced manufacturing keep widening the revenue base. The main drivers are as follows. Product pipeline. New launches in regulated markets add revenue. Brand trust. Respiratory and chronic brands retain prescribers. Contract work. Other drug companies outsource formulations. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Strides Pharma Science performed financially?

Ans. Revenue rose from Rs 3,202 crore in FY22 to Rs 5,009 crore in FY26, a compound annual growth rate of 11.8%. Net profit grew from Rs 409 crore in FY25 to Rs 575 crore in FY26, a rise of 40.3%. In the June 2026 quarter, revenue grew 12.6% year on year to Rs 1,270 crore, while net profit rose 56.7% to Rs 165 crore. The company has a return on equity of 17.9%, a debt to equity ratio of 0.57 and a market capitalisation of Rs 9,491 crore. The stock trades at a P/E of 15.0, below the industry P/E of 36.0. Looking ahead, the company is leaning on new product launches in its regulated-market pipeline and improving utilisation of its plants. Profit can rise faster than revenue as volumes build on an existing cost base.

How has Cipla performed financially?

Ans. Revenue rose from Rs 22,044 crore in FY22 to Rs 29,045 crore in FY26, a compound annual growth rate of 7.1%. Net profit grew from Rs 2,559 crore in FY22 to Rs 3,870 crore in FY26, which works out to a compound annual growth rate of 10.9%. In the June 2026 quarter, revenue grew 1.6% year on year to Rs 7,330 crore. The company has a return on equity of 11.3%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 107,528 crore. The stock trades at a P/E of 32.0, below the industry P/E of 36.0. Looking ahead, the company is deepening its position in respiratory and complex generic products while expanding its consumer health and domestic prescription brands. A wide global footprint spreads its earnings across several markets.

How has Innova Captab performed financially?

Ans. Revenue rose from Rs 803 crore in FY22 to Rs 1,637 crore in FY26, a compound annual growth rate of 19.5%. Net profit grew from Rs 64.0 crore in FY22 to Rs 141 crore in FY26, which works out to a compound annual growth rate of 21.8%. In the June 2026 quarter, revenue grew 32.8% year on year to Rs 473 crore, while net profit rose 42.3% to Rs 44.1 crore. The company has a return on equity of 12.9%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 5,736 crore. The stock trades at a P/E of 37.2, above the industry P/E of 36.0. Looking ahead, the company combines contract manufacturing with its own branded generics business, which lets it capture more of the value chain. It has also been expanding capacity and widening its customer base.

What risks should investors check before buying US generics, respiratory and contract stocks?

Ans. Investors should check a few risks before buying US generics, respiratory and contract stocks. Regulatory checks. Plant inspections can affect approvals. Price pressure. Generic prices abroad can fall. Currency moves. Export earnings move with the rupee. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of US generics, respiratory and contract stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 26 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.